Key Clinical Takeaways from the Video
-
Lifelong Triple-Drug Immunosuppression Regimen
Lifelong combination of Calcineurin Inhibitors (Tacrolimus or Cyclosporine), Antimetabolites (Mycophenolate Mofetil), and Corticosteroids (Prednisolone) to continuously prevent graft rejection.
-
Daily Home Spirometry & Vital Tracking
Patients track their baseline FEV1 and FVC every morning. A sustained drop of 10% or more serves as an essential early warning of acute cellular rejection or infection before symptoms emerge.
-
Infection Surveillance & Prophylaxis
Strict prophylactic regimens against Cytomegalovirus (Valganciclovir), Pneumocystis jirovecii (Co-trimoxazole), and fungal pathogens (Voriconazole/Itraconazole).
-
Scheduled Surveillance Bronchoscopies
Routine surveillance bronchoscopies with transbronchial biopsies and bronchoalveolar lavage (BAL) at 1, 3, 6, and 12 months to detect occult rejection early.
-
Structured Rehabilitation & Lifestyle Resumption
Targeted physical therapy rebuilds peripheral muscle strength, corrects osteopenia, and restores cardiovascular endurance, allowing most recipients to return to desk work within 3 to 6 months.